Preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil for oral squamous cell carcinoma

Q3 · MEDICINE

Article

Author: Endo, M ; Takeishi, E ; Yamazaki, M ; Kanno, C ; Hasegawa, H ; Sato, E ; Monma, T ; Kaneko, T ; Kitabatake, T ; Kano, M

The objectives of this study were to evaluate survival in 141 patients with stage II-IV oral squamous cell carcinoma (OSCC) treated with preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil (IADCPIVF) via the superficial temporal artery, and to clarify the prognostic factors. The study population included 59 patients with stage II OSCC, 34 with stage III, and 48 with stage IV. After IADCPIVF, 139 patients underwent surgery; minimally invasive surgeries (MIS) including excisional biopsy were performed on 96 patients with a remarkably good response to IADCPIVF. The primary tumour response rate was 99.3% (complete response rate 56.7%, good partial response rate 17.0%, fair partial response rate 25.5%). Additionally, there were no serious adverse events associated with IADCPIVF. The 5-year overall survival rate was 74.6% (stage II 83.6%, stage III 72.7%, stage IV 64.8%). In the multivariate analysis of survival, T classification and clinical tumour response were significant prognostic factors. Eight (8.3%) of the patients who received MIS had primary recurrence and six were salvaged. In conclusion, IADCPIVF is safe and efficacious for treating OSCC, and MIS could reduce the extent of primary tumour resection in the case of a remarkably good response.

01 Mar 2020·European Journal of Hospital PharmacyQ4 · MEDICINE

Three cases of advanced cutaneous squamous cell carcinoma treated with a combination of carboplatin and epirubicin

Q4 · MEDICINE

Article

Author: Okamoto, Mayumi ; Kawai, Mikio ; Numata, Tomofumi ; Tanaka, Akio ; Moriwaki, Masaya ; Mizuno, Hayato ; Otsuka, Risa ; Hide, Michihiro ; Takahagi, Shunsuke ; Murakami, Emi ; Sueoka, Manami ; Kan, Takanobu

Advanced cutaneous squamous cell carcinoma (cSCC) with nodal and/or distal metastases or large local spreading is inoperable, and treatment options for patients are usually limited to chemotherapy and radiation. The National Comprehensive Cancer Network (NCCN) Guidelines include some regimens of cisplatin- (CDDP) based systemic therapies, but no chemotherapy has yet been established for advanced cSCC.1 Peplomycin sulfate, bleomycin, and irinotecan are licensed for cSCC in Japan but are not commonly used in actual clinical practice because of their low efficacy and severe side effects (such as interstitial pneumonia, myelosuppression, and adverse digestive symptoms). CA regimen, the combination of CDDP and adriamycin (ADM), has been reported to show a response rate of about 60% for advanced cSCC,2 whereas other …

100 Deals associated with Peplomycin Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
D02063	-	L01XX	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lung Cancer	Japan	Nippon Kayaku Co., Ltd.	03 Oct 1983
Lymphoma	Japan	Nippon Kayaku Co., Ltd.	03 Oct 1983
Prostatic Cancer	Japan	Nippon Kayaku Co., Ltd.	03 Oct 1983
Squamous Cell Carcinoma	Japan	Nippon Kayaku Co., Ltd.	03 Oct 1983
Head and Neck Neoplasms	Japan	Nippon Kayaku Co., Ltd.	25 Oct 1980
Skin Neoplasms	Japan	Nippon Kayaku Co., Ltd.	25 Oct 1980

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis